NCT00104884 2023-06-28
FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Eastern Cooperative Oncology Group
Phase 2 Terminated
Clinical Trials
8 trialsNCT00765102 2019-11-25
Trial of Romidepsin and Bortezomib for Multiple Myeloma
Celgene
Phase 2 Terminated
NCT00383565 2014-05-20
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00098527 2013-07-02
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00079443 2013-07-01
FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00084461 2013-06-04
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00091195 2013-03-19
Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00087295 2012-11-02
S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium
SWOG Cancer Research Network
Phase 2 Terminated